{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:11Z","timestamp":1787003651144,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23491-0","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:10:29Z","timestamp":1763075429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Haiyin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Fawsitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Orishaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"23491_CR1","doi-asserted-by":"crossref","unstructured":"Menges, D. et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur. Urol. Oncol. (2022).","DOI":"10.1016\/j.euo.2022.04.007"},{"key":"23491_CR2","doi-asserted-by":"publisher","first-page":"102441","DOI":"10.1016\/j.ctrv.2022.102441","volume":"110","author":"G Fallara","year":"2022","unstructured":"Fallara, G. et al. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis. Cancer Treat. Rev. 110, 102441 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"23491_CR3","unstructured":"National Cancer Institute Surveillance, E. & End Results (SEER) Program. Cancer Stat Facts Prostate Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"7","key":"23491_CR4","first-page":"645","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor, O. & de Bono, J. S. Metastatic Prostate Cancer N Engl. J. Med., 378(7): 645\u2013657. (2018).","journal-title":"Metastatic Prostate Cancer N Engl. J. Med."},{"issue":"8","key":"23491_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic Hormone-Sensitive prostate cancer. N Engl. J. Med. 373 (8), 737\u2013746 (2015).","journal-title":"N Engl. J. Med."},{"issue":"10024","key":"23491_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387 (10024), 1163\u20131177 (2016).","journal-title":"Lancet"},{"issue":"1","key":"23491_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for Metastatic, Castration-Sensitive prostate cancer. N Engl. J. Med. 381 (1), 13\u201324 (2019).","journal-title":"N Engl. J. Med."},{"key":"23491_CR8","unstructured":"Clarke, N. W. et al. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol.  30, 1992\u20132003 (2019). Ann. Oncol. 31 (3), 442 (2020)."},{"issue":"2","key":"23491_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard First-Line therapy in metastatic prostate cancer. N Engl. J. Med. 381 (2), 121\u2013131 (2019).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"23491_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in Metastatic, Castration-Sensitive prostate cancer. N Engl. J. Med. 377 (4), 352\u2013360 (2017).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"23491_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl. J. Med. 377 (4), 338\u2013351 (2017).","journal-title":"N Engl. J. Med."},{"issue":"5","key":"23491_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes, M. R. et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29 (5), 1235\u20131248 (2018).","journal-title":"Ann. Oncol."},{"issue":"5","key":"23491_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jval.2019.11.007","volume":"23","author":"HE Aschmann","year":"2020","unstructured":"Aschmann, H. E. et al. Informing patient-centered care through stakeholder engagement and highly stratified quantitative benefit-harm assessments. Value Health. 23 (5), 616\u2013624 (2020).","journal-title":"Value Health"},{"key":"23491_CR14","doi-asserted-by":"crossref","unstructured":"Matsukawa, A. et al. An updated systematic review and network Meta-Analysis of First-Line triplet vs. Doublet therapies for metastatic Hormone-Sensitive prostate cancer. Cancers (Basel) 17 (2) (2025).","DOI":"10.3390\/cancers17020205"},{"issue":"12","key":"23491_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and survival in Metastatic, Hormone-Sensitive prostate cancer. N Engl. J. Med. 386 (12), 1132\u20131142 (2022).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"23491_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"C Zurth","year":"2019","unstructured":"Zurth, C. et al. Drug-Drug interaction potential of darolutamide: in vitro and clinical studies. Eur. J. Drug Metab. Pharmacokinet. 44 (6), 747\u2013759 (2019).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"23491_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40265-022-01831-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Rezvilutamide: first approval. Drugs 83 (2), 189\u2013193 (2023).","journal-title":"Drugs"},{"issue":"10","key":"23491_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","volume":"23","author":"W Gu","year":"2022","unstructured":"Gu, W. et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 23 (10), 1249\u20131260 (2022).","journal-title":"Lancet Oncol."},{"key":"23491_CR19","unstructured":"Dias, S. et al. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials (Report by the Decision Support Unit, 2011)."},{"issue":"4","key":"23491_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin, D. C. et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 14 (4), 429\u2013437 (2011).","journal-title":"Value Health"},{"issue":"4","key":"23491_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen, J. P. et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 14 (4), 417\u2013428 (2011).","journal-title":"Value Health"},{"issue":"10","key":"23491_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2471\/BLT.16.174326","volume":"94","author":"S Kanters","year":"2016","unstructured":"Kanters, S. et al. Use of network meta-analysis in clinical guidelines. Bull. World Health Organ. 94 (10), 782\u2013784 (2016).","journal-title":"Bull. World Health Organ."},{"issue":"1","key":"23491_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13643-022-02137-6","volume":"11","author":"DJ Fisher","year":"2022","unstructured":"Fisher, D. J. et al. Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change. Syst. Rev. 11 (1), 274 (2022).","journal-title":"Syst. Rev."},{"issue":"5_suppl","key":"23491_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","volume":"43","author":"DJ Fisher","year":"2025","unstructured":"Fisher, D. J. et al. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). J. Clin. Oncol. 43 (5_suppl), 20\u201320 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"23491_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","volume":"82","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa, T. et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic Hormone-sensitive prostate cancer: A systematic review and Meta-analysis. Eur. Urol. 82 (6), 584\u2013598 (2022).","journal-title":"Eur. Urol."},{"issue":"10","key":"23491_CR26","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1007\/s00432-023-04658-6","volume":"149","author":"M Dou","year":"2023","unstructured":"Dou, M. et al. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis. J. Cancer Res. Clin. Oncol. 149 (10), 7017\u20137027 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"23491_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/0284186X.2023.2241985","volume":"62","author":"Z Zhou","year":"2023","unstructured":"Zhou, Z. et al. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Acta Oncol. 62 (9), 1083\u20131090 (2023).","journal-title":"Acta Oncol."},{"issue":"3","key":"23491_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.prnil.2023.06.003","volume":"11","author":"YS Lee","year":"2023","unstructured":"Lee, Y. S. et al. Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials. Prostate Int. 11 (3), 159\u2013166 (2023).","journal-title":"Prostate Int."},{"key":"23491_CR29","doi-asserted-by":"publisher","first-page":"1148021","DOI":"10.3389\/fphar.2023.1148021","volume":"14","author":"T Jian","year":"2023","unstructured":"Jian, T. et al. Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front. Pharmacol. 14, 1148021 (2023).","journal-title":"Front. Pharmacol."},{"issue":"32","key":"23491_CR30","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: A Randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic Hormone-Sensitive prostate cancer. J. Clin. Oncol. 37 (32), 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"23491_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13696998.2024.2320001","volume":"27","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in china: a real-world observational study. J. Med. Econ. 27 (1), 361\u2013369 (2024).","journal-title":"J. Med. Econ."},{"issue":"20","key":"23491_CR32","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi, K. N. et al. Apalutamide in patients with metastatic Castration-Sensitive prostate cancer: final survival analysis of the Randomized, Double-Blind, phase III TITAN study. J. Clin. Oncol. 39 (20), 2294\u20132303 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"23491_CR33","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30 (12), 1992\u20132003 (2019).","journal-title":"Ann. Oncol."},{"issue":"2","key":"23491_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis, G. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic Non castrate prostate cancer: impact of metastatic burden and Long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur. Urol. 70 (2), 256\u2013262 (2016).","journal-title":"Eur. Urol."},{"issue":"2","key":"23491_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14 (2), 149\u2013158 (2013).","journal-title":"Lancet Oncol."},{"issue":"11","key":"23491_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36 (11), 1080\u20131087 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"23491_CR37","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20 (5), 686\u2013700 (2019).","journal-title":"Lancet Oncol."},{"issue":"6","key":"23491_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle, A. P. et al. Abiraterone in High- and Low-risk metastatic Hormone-sensitive prostate cancer. Eur. Urol. 76 (6), 719\u2013728 (2019).","journal-title":"Eur. Urol."},{"issue":"3","key":"23491_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James, N. D. et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int. J. Cancer. 151 (3), 422\u2013434 (2022).","journal-title":"Int. J. Cancer"},{"issue":"2","key":"23491_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45 (2), 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"23491_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias, S. et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Mak. 33 (5), 607\u2013617 (2013).","journal-title":"Med. Decis. Mak."},{"issue":"5","key":"23491_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","volume":"29","author":"CL Vale","year":"2018","unstructured":"Vale, C. L. et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann. Oncol. 29 (5), 1249\u20131257 (2018).","journal-title":"Ann. Oncol."},{"key":"23491_CR43","unstructured":"Dias, S. et al. NICE decision support unit technical support documents. In NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials (National Institute for Health and Care Excellence (NICE), 2014)."},{"issue":"4","key":"23491_CR44","first-page":"583","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter, D. J. et al. Bayesian Measures model. Complex. fit. 64(4): 583\u2013639. (2002).","journal-title":"Bayesian Measures model. Complex. fit."},{"issue":"1","key":"23491_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","volume":"68","author":"KM Rhodes","year":"2015","unstructured":"Rhodes, K. M., Turner, R. M. & Higgins, J. P. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J. Clin. Epidemiol. 68 (1), 52\u201360 (2015).","journal-title":"J. Clin. Epidemiol."},{"key":"23491_CR46","doi-asserted-by":"crossref","unstructured":"Lunn, D. et al. The BUGS Book: A Practical Introduction to Bayesian Analysis. Texts in Statistical Science 381  (CRC Press, 2013).","DOI":"10.1201\/b13613"},{"key":"23491_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","volume":"173","author":"C Ciccarese","year":"2022","unstructured":"Ciccarese, C. et al. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. Eur. J. Cancer. 173, 276\u2013284 (2022).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"23491_CR48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","volume":"5","author":"S Roy","year":"2022","unstructured":"Roy, S. et al. Addition of docetaxel to androgen receptor Axis-targeted therapy and androgen deprivation therapy in metastatic Hormone-sensitive prostate cancer: A network Meta-analysis. Eur. Urol. Oncol. 5 (5), 494\u2013502 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"23491_CR49","doi-asserted-by":"publisher","first-page":"955925","DOI":"10.3389\/fphar.2022.955925","volume":"13","author":"T Jian","year":"2022","unstructured":"Jian, T. et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front. Pharmacol. 13, 955925 (2022).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23491-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23491-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23491-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:03:03Z","timestamp":1763078583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23491-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23491"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23491-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: HT owns shares in the consulting company Clifton Insight, and PO and CF are employees of Clifton Insight, which has received fees from Amicus, Baxter, Bayer, Daiichi-Sankyo, Eisai, Lundbeck, Merck, Novo Nordisk, Pfizer, Roche, and UCB. RX and YZ are employees of the Bayer Healthcare Company Ltd. Non-financial interests: HW and NX declare that they have no conflict of interests. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39857"}}